Carotid Artery Disease Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Carotid artery disease is the atherosclerotic narrowing of the internal carotid arteries — the principal blood vessels supplying the cerebral hemispheres — by plaques composed of lipid, fibrous tissue, and calcified material. When a plaque ruptures or significantly narrows the vessel, it can cause transient ischaemic attack (TIA — a brief episode of neurological dysfunction resolving within 24 hours) or ischaemic stroke — a devastating, potentially fatal or permanently disabling event. Carotid artery disease accounts for approximately 15–20% of all ischaemic strokes, making its early detection and treatment a major public health priority.

Treatment of carotid artery disease encompasses two parallel strategies that must proceed simultaneously: aggressive medical risk factor modification to stabilise plaque and prevent further events, and mechanical intervention — either surgical carotid endarterectomy (CEA) or percutaneous carotid artery stenting (CAS) — to remove or scaffold the stenosis and prevent embolic stroke. The decision to intervene and the choice of technique are guided by the degree of stenosis (measured by duplex ultrasound, CT angiography, or MR angiography), the patient's symptomatic status (recent TIA or ipsilateral stroke versus asymptomatic), surgical risk profile, and local institutional expertise.

The carotid arteries are examined in the neck by clinical palpation of the carotid pulse and auscultation for bruits, but these findings are neither sensitive nor specific for significant disease. Duplex ultrasound is the first-line non-invasive diagnostic tool, providing both anatomical plaque characterisation and haemodynamic measurement of peak systolic velocity — a proxy for stenosis severity. CT angiography provides three-dimensional vessel and plaque characterisation, while catheter angiography is reserved for cases of discordant non-invasive imaging.

Symptomatic carotid stenosis — defined as greater than 50% stenosis (NASCET criteria) on the side ipsilateral to a recent TIA or minor ischaemic stroke — is the primary and most urgent indication for carotid intervention. The absolute risk of recurrent stroke within the first two weeks of a TIA or minor stroke from carotid disease is approximately 10–15%, creating a narrow window of opportunity for intervention to prevent a potentially devastating completed stroke. The benefit of endarterectomy over medical therapy alone in symptomatic patients with 70–99% stenosis is overwhelmingly established by the NASCET and ECST randomised trials, with a two-year absolute risk reduction in ipsilateral stroke of approximately 17%.

Asymptomatic carotid stenosis — greater than 60–70% stenosis in patients without recent cerebrovascular symptoms — is a more controversial indication for intervention, as the annual stroke risk from modern optimal medical therapy is relatively low (approximately 1% per year at experienced medical centres). The ACAS and ACST randomised trials demonstrated a modest but significant benefit of endarterectomy over medical therapy in selected asymptomatic patients, with benefit accruing over three to five years. Current guidelines recommend individualised discussion of intervention in asymptomatic patients with stenosis above 70%, particularly in patients with contralateral occlusion, silent ischaemic lesions on MRI, or plaque instability features on imaging.

Ideal surgical candidates for carotid endarterectomy are patients under 80 years with symptomatic carotid stenosis above 50% who have had a recent TIA or non-disabling stroke (within six months, preferably within two weeks for maximum benefit), acceptable general anaesthetic and surgical risk (no recent myocardial infarction within six weeks, no severe cardiac or pulmonary comorbidity), and a modified Rankin Score of 3 or less indicating preserved functional status. The perioperative stroke and death risk of endarterectomy must not exceed 6% to justify intervention in symptomatic patients — this threshold must be achievable at the operating centre.

Contraindications to carotid endarterectomy include complete carotid occlusion (not amenable to surgery), distal internal carotid disease extending beyond the surgical field, active stroke with major deficit (surgery in acute stroke with dense hemiplegia increases haemorrhagic transformation risk), recent large hemispheric infarction (requires waiting period of four to six weeks), severe contralateral carotid occlusion with dependent collateral flow, and life expectancy below two years from comorbid illness. Carotid artery stenting (CAS) is the preferred intervention in anatomically high-risk patients — prior neck irradiation, contralateral cranial nerve palsy, hostile neck from prior surgery — and in patients with serious cardiac conditions contraindicating general anaesthesia.

Carotid endarterectomy (CEA) — the surgical gold standard — involves incising the common carotid artery and its bifurcation in the neck under general or local anaesthesia, removing the atherosclerotic plaque under direct vision, and closing the artery with either primary suture or a patch of vein or PTFE graft to prevent restenosis. A temporary shunt may be inserted to maintain cerebral perfusion during the period of carotid clamping. Intraoperative neurophysiological monitoring (somatosensory evoked potentials, EEG, or TCD of the middle cerebral artery) helps detect cerebral ischaemia during clamping and guides the decision to use a shunt. Eversion endarterectomy — transecting the internal carotid artery and everting the plaque-bearing segment — avoids patch closure and has equivalent outcomes to conventional endarterectomy with patching.

Carotid artery stenting (CAS) is performed via a percutaneous transfemoral approach under local anaesthesia and moderate sedation. A catheter is advanced from the femoral artery to the carotid bifurcation, a distal embolic protection device is deployed beyond the stenosis, and a self-expanding stent is deployed across the plaque. CAS is non-inferior to CEA in experienced hands for symptomatic stenosis in patients below 70 years (CREST trial), with slightly higher peri-procedural stroke rates but lower myocardial infarction and cranial nerve injury rates. For patients above 70 years, CEA shows superior outcomes due to greater embolic risk from the calcified aortic arch during CAS catheter manipulation in older patients.

Carotid endarterectomy is one of the most evidence-based surgical interventions in medicine, with benefit established by multiple large randomised trials over three decades. In symptomatic patients with 70–99% stenosis, CEA reduces five-year ipsilateral stroke risk by approximately 48% compared to medical therapy alone (NASCET trial). The absolute benefit is greatest in patients operated on within two weeks of the index TIA or minor stroke — delay beyond this window substantially reduces the protective benefit as the high-risk period for early recurrent stroke passes. In women with symptomatic high-grade stenosis, benefit was demonstrated only above 70% stenosis in NASCET analysis, reinforcing careful patient selection.

Medical therapy has improved dramatically since the NASCET and ECST era — high-intensity statins (atorvastatin 40–80 mg), dual antiplatelet therapy, rigorous blood pressure control, and smoking cessation now reduce the annual stroke risk from asymptomatic disease to approximately 1%. This means that the absolute benefit of surgical intervention in asymptomatic patients is smaller today than demonstrated in the original ACAS and ACST trials, and ongoing trials (CREST-2, ECST-2) are re-evaluating surgery versus optimal medical therapy alone in this population. Nevertheless, endarterectomy remains guideline-recommended in asymptomatic patients with stenosis above 70% at centres with demonstrated perioperative complication rates below 3%.

The primary risk of carotid endarterectomy is perioperative stroke — caused by embolisation of plaque material or thrombotic occlusion during clamping — affecting approximately 1.5–3% of patients at experienced centres. Ipsilateral stroke during the perioperative period carries high mortality and disability, underscoring the importance of operating at centres with proven low stroke and death rates. Cranial nerve injury — most commonly the hypoglossal, vagus, or marginal mandibular nerve — occurs in 5–10% of patients and is usually temporary, manifesting as tongue weakness, hoarseness, or lip droop; permanent nerve injury is uncommon (below 1%).

Wound haematoma — an expanding neck haematoma from inadequate surgical haemostasis — occurs in 2–5% of cases and may compress the airway, requiring urgent surgical evacuation. Cardiovascular events (myocardial infarction, cardiac death) occur in 1–3% of cases reflecting the high cardiovascular comorbidity burden of patients with carotid atherosclerosis. Restenosis of the endarterectomised vessel occurs in approximately 5–10% at ten years, generally managed medically unless progressing to symptomatic high-grade re-stenosis. Hyperperfusion syndrome — sudden ipsilateral headache, seizures, and focal neurological signs due to flooding of long-ischaemic cerebral vasculature after reperfusion — is a rare (1%) but serious complication requiring urgent blood pressure control.

After carotid endarterectomy, patients are monitored in a high-dependency setting for 12–24 hours for blood pressure fluctuations (both hypo and hypertension are common in the first 24 hours), neurological status changes, and neck haematoma. Blood pressure is titrated to a target of 120–140 systolic during the immediate post-operative period. Most patients are fit for discharge within one to two days of surgery. The neck wound heals within two weeks; driving is usually permitted after two to four weeks provided no neurological deficits are present.

Lifelong dual antiplatelet therapy (aspirin plus clopidogrel for one to three months, then aspirin alone), high-intensity statin therapy, and antihypertensive medications are maintained indefinitely after intervention. Blood pressure target should be below 130/80 mmHg. Duplex ultrasound surveillance of the operated carotid is performed at one to three months post-operatively, then annually to detect restenosis and monitor the contralateral carotid. Neurological follow-up is arranged by the stroke physician or neurologist who managed the initial TIA or stroke event. Lifestyle modifications — smoking cessation, Mediterranean diet, regular aerobic exercise, diabetes management — are essential to reduce cardiovascular risk and prevent progression of disease in other vessels.

Carotid endarterectomy in the United States costs USD 20,000–50,000 including hospital stay and anaesthesia; carotid stenting adds device costs, often exceeding USD 30,000–60,000. In the UK, NHS covers eligible patients without charge; private CEA costs GBP 8,000–18,000. In India, high-quality CEA is available at Apollo Hospitals, Fortis, and Narayana Health for USD 3,000–7,000 — a saving of 80–90% versus US prices. Carotid stenting (CAS) is available at the same centres for USD 5,000–10,000 including device and procedure costs.

Thailand (Bumrungrad, Samitivej) charges USD 8,000–15,000 for CEA; Turkey (Acibadem, Florence Nightingale) USD 5,000–12,000. Patients seeking carotid surgery abroad should ensure the centre has a dedicated stroke and vascular surgery programme with an experienced team performing high-volume CEA (above 50 procedures per year per surgeon), access to post-operative neurological and stroke care, and availability of intraoperative neurophysiological monitoring. The short post-operative recovery period (one to two days hospitalisation) makes international carotid surgery logistically feasible for well-selected patients.

Optimal medical therapy — high-intensity statins (atorvastatin 40–80 mg, rosuvastatin 20–40 mg), dual antiplatelet therapy, aggressive blood pressure control below 130/80 mmHg, smoking cessation, and lifestyle modification — is the foundation of carotid artery disease management for all patients and is the definitive treatment for low-grade stenosis below 50% or asymptomatic stenosis below 60–70%. Medical therapy has dramatically improved outcomes over the past two decades, reducing the annual stroke risk from asymptomatic carotid stenosis to below 1% in adherent patients on modern drug regimens. Carotid artery stenting (CAS) using self-expanding nitinol stents and distal embolic protection is an established alternative to surgical endarterectomy, particularly for anatomically high-risk surgical patients and those with contraindications to general anaesthesia.